Sector Update: Healthcare; Nuvo Research Debuts Pennsaid 2% in U.S., Atrium-Permira Plan of Arrangement Gets Investment Canada Nod

By
A A A

Healthcare stocks were mixed in the afternoon, but the S&P/TSX Healthcare Index was up 0.58%.

Valeant Pharmaceuticals (VRX.TO): +0.3%

Nuvo Research Inc. (NRI.TO): -1.7%

Atrium Innovations Inc. (ATB.TO): flat

Patheon Inc. (PTI.TO): -0.2%

Cml Healthcare Inc. (CLC.TO): flat

Prometic Life Sciences Inc. (PLI.TO): +3.8%

In company news, Atrium Innovations Inc. says that the $24-per-share acquisition of the company's outstanding shares by a group of investors backed by Permira funds has received approval from the Ministry of Industry, pursuant to the Investment Canada Act. The plan of arrangement also includes the acquisition by the company of all of its outstanding convertible debentures.

The arrangement, which is expected to close on February 13, 2014, also received approval from the Ukrainian competition authorities.

Also, Nuvo Research Inc's. 2% Pennsaid (diclofenac sodium topical solution) for osteoarthritis knee pain has been launched commercially in the U.S. today. U.S. sales and marketing rights for Pennsaid 2% are licensed to Mallinckrodt.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks:

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

Most Active by Volume

139,392,686
  • $5.41 ▼ 18.52%
108,086,733
  • $17.04 ▲ 1.61%
88,411,032
  • $42.085 ▼ 1.19%
35,897,863
  • $101.79 ▲ 0.21%
34,635,836
  • $46.68 ▲ 0.34%
31,162,075
  • $4.36 ▲ 12.37%
31,086,421
  • $26.21 ▲ 0.61%
30,930,862
  • $17.09 ▼ 2.95%
As of 9/18/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com